<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5//EN" "ep-patent-document-v1-5.dtd">
<!-- This XML data has been generated under the supervision of the European Patent Office -->
<ep-patent-document id="EP16700150B8W1" file="EP16700150W1B8.xml" lang="en" country="EP" doc-number="3242681" kind="B8" correction-code="W1" date-publ="20201125" status="c" dtd-version="ep-patent-document-v1-5">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>BDM Ver 1.7.2 (20 November 2019) -  2999001/0</B007EP></eptags></B000><B100><B110>3242681</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20201125</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>16700150.2</B210><B220><date>20160106</date></B220><B240><B241><date>20170802</date></B241><B242><date>20180531</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>15150219</B310><B320><date>20150106</date></B320><B330><ctry>EP</ctry></B330></B300><B400><B405><date>20201125</date><bnum>202048</bnum></B405><B430><date>20171115</date><bnum>201746</bnum></B430><B450><date>20200708</date><bnum>202028</bnum></B450><B452EP><date>20200206</date></B452EP><B480><date>20201125</date><bnum>202048</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61K  38/57        20060101AFI20160722BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>NEUARTIGE VERBINDUNGEN ZUR KREBSBEHANDLUNG</B542><B541>en</B541><B542>NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER</B542><B541>fr</B541><B542>NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DU CANCER</B542></B540><B560><B561><text>WO-A1-2013/135836</text></B561><B561><text>US-A1- 2002 132 981</text></B561><B562><text>VALENZUELA D ET AL: "Human secreted protein encoded by DNA clone vo33 1", GENESEQ,, 21 September 2000 (2000-09-21), XP002740580, [retrieved on 2001-01-26] &amp; WO 00/55375 A1 (ALPHAGENE INC [US]) 21 September 2000 (2000-09-21)</text></B562><B562><text>"Human protein modification and maintenance molecule (PMMM) protein #1", GENESEQ,, 4 December 2003 (2003-12-04), XP002740591, [retrieved on 2004-04-22] &amp; WO 03/100016 A2 (INCYTE CORP [US]; KHARE REENA [US]; BULLOCH SEAN A) 4 December 2003 (2003-12-04)</text></B562><B562><text>KLOTEN VERA ET AL: "Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype", EPIGENETICS, LANDES BIOSCIENCE, US, vol. 9, no. 9, 1 September 2014 (2014-09-01), pages 1290-1301, XP002740582, ISSN: 1559-2294 [retrieved on 2014-08-04]</text></B562><B562><text>ROSE MICHAEL ET AL: "Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours", CARCINOGENESIS, OXFORD UNIVERSITY PRESS, GB, vol. 35, no. 3, 1 March 2014 (2014-03-01), pages 727-736, XP002740583, ISSN: 0143-3334, DOI: 10.1093/CARCIN/BGT375 [retrieved on 2013-11-21]</text></B562><B562><text>MICHAEL ROSE: "Identifizierung und Validierung neuer DNA-Methylungsbiomarker zur Früherkennung von Harnblasentumoren sowie Charakterisierung des putativen Tumorsuppressorgens ITIH5 für das Harnblasen- und Mammakarzinom", INTERNET CITATION, 13 May 2013 (2013-05-13), pages 3PP.I-XIV, XP002740584, Retrieved from the Internet: URL:http://publications.rwth-aachen.de/rec ord/229798/files/4573.pdf [retrieved on 2015-06-03]</text></B562></B560></B500><B700><B720><B721><snm>DAHL, Edgar</snm><adr><str>An den Eichen 26</str><city>4721 Kelmis</city><ctry>BE</ctry></adr></B721><B721><snm>ROSE, Michael</snm><adr><str>Auf der Pief 41a</str><city>52134 Herzogenrath</city><ctry>DE</ctry></adr></B721><B721><snm>HUTH, Sebastian</snm><adr><str>Rödgener Str. 93</str><city>52080 Aachen</city><ctry>DE</ctry></adr></B721></B720><B730><B731><snm>QITHERA GmbH</snm><iid>101871613</iid><irf>TUA-PA01-PCT/EP</irf><adr><str>Talstraße 14</str><city>52525 Heinsberg</city><ctry>DE</ctry></adr></B731></B730><B740><B741><snm>Roth, Andy Stefan</snm><iid>101356955</iid><adr><str>Dr. Roth Patentanwaltskanzlei 
Kaistrasse 5</str><city>40221 Düsseldorf</city><ctry>DE</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>EP2016050100</anum></dnum><date>20160106</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2016110496</pnum></dnum><date>20160714</date><bnum>201628</bnum></B871></B870></B800></SDOBI>
</ep-patent-document>
